↓ Skip to main content

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

Overview of attention for article published in BMC Cancer, September 2014
Altmetric Badge

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
Published in
BMC Cancer, September 2014
DOI 10.1186/1471-2407-14-674
Pubmed ID
Authors

Mark Linch, Spyridon Gennatas, Stanislav Kazikin, Jhangir Iqbal, Ranga Gunapala, Kathryn Priest, Joanne Severn, Alison Norton, Bee Ayite, Jaishree Bhosle, Mary O’Brien, Sanjay Popat

Abstract

Malignant mesothelioma (MM) carries a poor prognosis and response rates to palliative chemotherapy remain low. Identifying patients with MM that are unlikely to respond to chemotherapy could prevent futile treatments and improve patient quality of life. Studies have suggested that soluble mesothelin is a potential biomarker for early diagnosis and prognosis of MM. We set out to explore the utility of serum mesothelin in routine clinical practice.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 29%
Student > Postgraduate 3 13%
Researcher 3 13%
Other 2 8%
Student > Bachelor 2 8%
Other 3 13%
Unknown 4 17%
Readers by discipline Count As %
Medicine and Dentistry 11 46%
Biochemistry, Genetics and Molecular Biology 2 8%
Environmental Science 1 4%
Business, Management and Accounting 1 4%
Veterinary Science and Veterinary Medicine 1 4%
Other 4 17%
Unknown 4 17%